Three groups, of five
patients each, were administered escalating doses of Elenagen™. Only minimal
Grade I side effects were observed in some patients.

Elenagen™ was able to cease disease progression

in patients with breast, ovary, lung, renal cancer and melanoma. Patients
admitted into our trial were “salvage patients” who have failed all other available
treatment protocols and were in the active disease progression stage. The main
goal was to stop the disease progression, which we have achieved.

Restoring tumor sensitivity to chemotherapy.

All patients admitted to the clinical
trials have already failed multiple lines of chemotherapy. However, after
treatment with Elenagen™, the
patients were able to succesfully respond to new rounds of chemotherapy.

Future Phase II clinical trials

CureLab
Oncology, Inc. is planning to conduct US and international phase II clinical
trials in following diseases: